SER Company Profile and Key Details

SER has shown mixed momentum, gaining 16.19% over the past week and -40.31% over the past quarter, though year-to-date performance is up 50.03%. Short-term trend indicators are bullishly aligned (SMA20 -16.18%, SMA50 -25.13%, SMA200 -59.25%). The stock’s 14-day RSI is 40.43 (neutral), while the ATR of 0.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -77.15% below its high and over 17.98% above its low. Average 10-day trading volume of 55.41 thousand shares is below the 3-month average of 3.59 million, indicating normal recent market interest.

Serina Therapeutics, Inc. generated EPS of $nan over the past year. Five-year average earnings growth is 33.3%. Wall Street analysts project EPS growth of 2.49% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $15.00. The high target offers 689.47% upside. The low target suggests 689.47% downside. The mean target is $15.00. This offers 689.47% upside. Serina Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 25, 2026, missed forecasts by -38.0%. The prior quarter beat by -5.64%. Over the last six quarters, Apple has recorded several small beats. These include -164.29% in March 24, 2025.

Serina Therapeutics, Inc. (AMEX:SER) closed at $1.90 USD, gaining $0.08 (4.57%) from the previous close of $1.82. The stock is currently mid-range between its 52-week high and low $1.22 and $7.92. With a market capitalization of about $19.00 million, Serina Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.10). Key stats such as the average daily volume over the past year has been around 3.41 million shares, volume is running light vs its 52-week average. Headquartered in Huntsville, AL, Serina Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven A. Ledger, the company employs approximately 12 people and listed since January 21, 2000. Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.

Serina Therapeutics, Inc. has 10.25 million shares outstanding. The public float is 3.08 million shares, elevated short interest at 0.89% of float. This equals 51.31 thousand shares. The short ratio is 1.48 days. Institutional investors hold 5.94% of the float. Insiders own 40.96%. Bailey Gregory holds 67.24 thousand shares, MINTZ STEVEN has 17.44 thousand shares and Moreadith Randall has 0.00 shares. Over the past six months, insider transactions show net selling. They sold 136.50 thousand shares across 25 transactions.

Serina Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.11. This means the shares are trading below this model’s fair value.

Serina Therapeutics, Inc. trades at a P/E ratio of -1.01, slightly below the S&P 500 average, with a price-to-sales ratio of 145.77 and a price-to-book ratio of -521.89 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.05, also below market averages.

Our AI price prediction model suggests that Serina Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.05%, with price expected at $1.92 by May 18, 2026, within a range of $1.46 to $2.40 3-Month Outlook: Projected fall of -36.84%, reaching $1.20 by July 31, 2026, with a range of $1.04 to $1.37. 1-Year Outlook: Projected loss of -48.42%, with price at $0.98 by May 04, 2027, within a range of $0.51 to $1.32.

Serina Therapeutics, Inc. (AMEX:SER) shares are up 50.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Serina Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.67, suggesting 619.47% upside. Our AI forecast model points to short-term strength (1.05% over two weeks), a medium-term fall (-36.84% over three months), and a longer-term loss (-48.42% over one year), with expected trading ranges indicating moderate volatility.